These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 35642667)

  • 41. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
    Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
    Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Introducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations.
    Nenclares P; Rullan A; Tam K; Dunn LA; St John M; Harrington KJ
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-16. PubMed ID: 35522916
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck Cancer.
    Haas M; Lein A; Fuereder T; Brkic FF; Schnoell J; Liu DT; Kadletz-Wanke L; Heiduschka G; Jank BJ
    Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839241
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of immune-related lncRNA panel for predicting immune checkpoint blockade and prognosis in head and neck squamous cell carcinoma.
    Li Q; Shen Z; Shen Y; Deng H; Shen Y; Wang J; Zhan G; Zhou C
    J Clin Lab Anal; 2022 Jun; 36(6):e24484. PubMed ID: 35561269
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.
    Van den Bossche V; Zaryouh H; Vara-Messler M; Vignau J; Machiels JP; Wouters A; Schmitz S; Corbet C
    Drug Resist Updat; 2022 Jan; 60():100806. PubMed ID: 35121337
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel Insights of Anti-EGFR Therapy in HNSCC: Combined with Immunotherapy or Not?
    Dong L; Wang Y; Yao X; Ren Y; Zhou X
    Curr Oncol Rep; 2023 Feb; 25(2):93-105. PubMed ID: 36585960
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular Subtypes Based on Cell Differentiation Trajectories in Head and Neck Squamous Cell Carcinoma: Differential Prognosis and Immunotherapeutic Responses.
    Huang ZD; Liu ZZ; Liu YY; Fu YC; Lin LL; Hu C; Gu HY; Wei RX
    Front Immunol; 2021; 12():791621. PubMed ID: 35003112
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.
    Evrard D; Hourseau M; Couvelard A; Paradis V; Gauthier H; Raymond E; Halimi C; Barry B; Faivre S
    Oncoimmunology; 2020 Nov; 9(1):1844403. PubMed ID: 33299655
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The 5-Ws of immunotherapy in head and neck cancer.
    Botticelli A; Mezi S; Pomati G; Cerbelli B; Di Rocco C; Amirhassankhani S; Sirgiovanni G; Occhipinti M; Napoli V; Emiliani A; Mazzuca F; Tomao S; Nuti M; Marchetti P
    Crit Rev Oncol Hematol; 2020 Sep; 153():103041. PubMed ID: 32629362
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.
    Miyauchi S; Kim SS; Pang J; Gold KA; Gutkind JS; Califano JA; Mell LK; Cohen EEW; Sharabi AB
    Clin Cancer Res; 2019 Jul; 25(14):4211-4223. PubMed ID: 30814108
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
    Ferris RL; Spanos WC; Leidner R; Gonçalves A; Martens UM; Kyi C; Sharfman W; Chung CH; Devriese LA; Gauthier H; Chiosea SI; Vujanovic L; Taube JM; Stein JE; Li J; Li B; Chen T; Barrows A; Topalian SL
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083421
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ferroptosis Signature Shapes the Immune Profiles to Enhance the Response to Immune Checkpoint Inhibitors in Head and Neck Cancer.
    Chung CH; Lin CY; Chen CY; Hsueh CW; Chang YW; Wang CC; Chu PY; Tai SK; Yang MH
    Adv Sci (Weinh); 2023 May; 10(15):e2204514. PubMed ID: 37026630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers.
    Chen SMY; Popolizio V; Woolaver RA; Ge H; Krinsky AL; John J; Danis E; Ke Y; Kramer Y; Bian L; Nicklawsky AG; Gao D; Liu S; Chen Z; Wang XJ; Wang JH
    J Exp Clin Cancer Res; 2022 Apr; 41(1):123. PubMed ID: 35366939
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Circulating Tumour Cell Expression of Immune Markers as Prognostic and Therapeutic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
    Payne K; Pugh M; Brooks J; Batis N; Taylor G; Nankivell P; Mehanna H
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153130
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy.
    Puntigam LK; Jeske SS; Götz M; Greiner J; Laban S; Theodoraki MN; Doescher J; Weissinger SE; Brunner C; Hoffmann TK; Schuler PJ
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707816
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC.
    Ding Y; Chu L; Cao Q; Lei H; Li X; Zhuang Q
    BMC Cancer; 2023 Jan; 23(1):45. PubMed ID: 36639648
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.
    Aggarwal C; Prawira A; Antonia S; Rahma O; Tolcher A; Cohen RB; Lou Y; Hauke R; Vogelzang N; P Zandberg D; Kalebasty AR; Atkinson V; Adjei AA; Seetharam M; Birnbaum A; Weickhardt A; Ganju V; Joshua AM; Cavallo R; Peng L; Zhang X; Kaul S; Baughman J; Bonvini E; Moore PA; Goldberg SM; Arnaldez FI; Ferris RL; Lakhani NJ
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35414591
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
    Poulose JV; Kainickal CT
    World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Personalized cancer vaccination in head and neck cancer.
    Shibata H; Zhou L; Xu N; Egloff AM; Uppaluri R
    Cancer Sci; 2021 Mar; 112(3):978-988. PubMed ID: 33368875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.